Blood pressure medication recalls create a specific kind of risk: the recalled product may be part of a daily treatment plan, but stopping suddenly can also be unsafe. That is why the FDA blood pressure medication recall list has to be read at the bottle level, not as a broad warning about every hypertension drug.
Most FDA drug recalls are narrow. A notice may apply to one manufacturer, one lot, one strength, one package size, or one combination product. Two patients can both take losartan and have different recall status because their prescriptions came from different labelers. A pharmacy can refill the same generic name from a new supplier without changing the prescribing instructions. A caregiver can move tablets into a weekly organizer and lose the lot number that determines whether the recall applies.
RecallTracker tracks {{RECALL_COUNT}} recalls across {{AGENCY_COUNT}} agencies, including {{FDA_COUNT}} FDA records, {{CPSC_COUNT}} CPSC records, and {{NHTSA_COUNT}} NHTSA records. Across the broader recall system, agencies logged {{RECALLS_2025}} recall actions in 2025 and {{RECALLS_2026_YTD}} so far in {{CURRENT_YEAR}}. For prescription blood pressure medication, the FDA is the central source because it oversees drug quality, labeling, contamination, potency, and manufacturing controls.
If you have the bottle or carton in front of you, start with the identifiers printed on the package. The fastest first pass is to scan a product barcode, then compare the product name, manufacturer, National Drug Code, lot number, strength, and expiration date against the recall notice or your pharmacy record. A general search for “fda blood pressure medication recall list” should lead to a precise check, not a decision to skip medication without pharmacist or prescriber guidance.
The FDA blood pressure medication recall list is not a single list of every unsafe hypertension drug. It is a stream of recall notices, enforcement reports, company announcements, and product-specific actions. The exact match matters because prescription drugs are traceable by product identifiers, not by the broad condition they treat.
For consumers, the recall question usually starts with one of these medications or medication families:
Those names are useful search terms, but they do not prove that your bottle is affected. A generic drug name identifies the active ingredient. A recall notice usually identifies the product as sold: the labeler, dosage form, strength, package configuration, lot number, and sometimes the distribution dates.
That distinction is the reason patients often get conflicting information online. One source says a blood pressure medication was recalled. Another says the same drug is still available. Both can be true. A recalled lot from one manufacturer can be removed while other manufacturers continue supplying the same active ingredient. A recall can involve combination tablets while the single-ingredient product remains outside the notice. A recall can also sit at the wholesale or pharmacy level without requiring every patient at home to return a bottle.
The table below shows how to interpret the names most often tied to FDA blood pressure medication recall list searches.
| Medication or product family | Why it appears in recall searches | What determines whether your bottle is affected | Practical check |
|---|---|---|---|
| Valsartan | Central drug name in the long-running ARB impurity recall history | Manufacturer, lot, NDC, strength, and whether it is a combination product | Compare the bottle label and lot number against the specific notice |
| Losartan | Common ARB with repeated consumer recall questions after nitrosamine concerns | Labeler, lot, package size, and distribution window | Ask the pharmacy whether your exact fill came from affected stock |
| Irbesartan | Part of the ARB class that consumers associate with impurity recalls | Manufacturer and lot-level scope | Check the full product identity, not only the generic name |
| Valsartan-HCTZ | Combination product that may be confused with plain valsartan or plain hydrochlorothiazide | Full two-ingredient formula plus strength and lot | Match both ingredients and both strengths |
| Losartan-HCTZ | Combination product often searched by patients who remember only “losartan” | Labeler, lot, strength pair, and package details | Read the complete prescription label before searching |
| Quinapril combinations | Appears in searches because nitrosamine concerns affected some ACE inhibitor products | Exact quinapril or quinapril-HCTZ product and manufacturer | Confirm whether the current bottle is from the named labeler |
| Amlodipine combinations | Consumers may remember amlodipine while the recall issue involves a paired ingredient | Whether the product is amlodipine alone or amlodipine with another active ingredient | Verify the full medication name and NDC |
| Metoprolol products | Recall checks can differ by release type and package | Tartrate vs succinate ER, strength, lot, and manufacturer | Do not treat all metoprolol labels as identical |
FDA drug recalls also have classifications. Class I recalls involve the highest level of health risk. Class II recalls involve a lower but still meaningful risk, often temporary or medically reversible harm or a remote probability of serious harm. Class III recalls are not likely to cause adverse health consequences. Blood pressure medication recalls often require careful reading because a lower-risk quality defect may still involve a product a patient takes every day.
Distribution level matters too. A recall may be directed to wholesalers, pharmacies, clinics, or consumers. If the recall stops at the wholesale level, it may not mean the bottle in your medicine cabinet is part of the action. If the recall reaches the consumer level, the notice should explain whether to stop using the product, contact a pharmacist, return it, or arrange replacement stock.
The safest rule is plain: do not act on the generic drug name alone. Match the exact bottle. If the pharmacy label is hard to read or the lot number is missing, use the pharmacy record rather than guessing.
The modern search pattern around blood pressure medication recalls is heavily influenced by angiotensin II receptor blockers, usually called ARBs. Valsartan became the best-known name because several recalls beginning in 2018 involved certain products contaminated with nitrosamine impurities. Later consumer concern expanded to other ARBs, including losartan and irbesartan, and to combination products that paired an ARB with hydrochlorothiazide.
The specific impurities most often discussed in the ARB recall history include NDMA and NDEA, nitrosamine compounds that raised long-term exposure concerns. These recalls were not based on consumers seeing a damaged tablet or smelling something unusual in the bottle. The issue was tied to manufacturing chemistry, supplier controls, and impurity testing. That made the recalls harder for patients to interpret because the product could look normal while still being covered by a notice.
That history still affects behavior in {{CURRENT_YEAR}} for three reasons.
First, blood pressure medications are maintenance drugs. People take them for months or years, so a recall naturally raises questions about past exposure as well as current replacement.
Second, generic supply changes are common. A patient may receive a refill from a different labeler without recognizing that the recall status has changed. The tablet color, shape, or imprint may also change, which can trigger concern even when there is no active recall for that lot.
Third, older headlines continue to circulate. A patient searching today may find older valsartan or losartan news and assume it describes the bottle currently in hand. Sometimes it does. Often it does not. The only way to know is to match the product identifiers.
The ARB pattern also explains why broad search terms are risky. “Losartan recall” is more precise than “blood pressure medication recall,” but it is still incomplete. “Losartan potassium tablets, 50 mg, manufactured by a named labeler, lot number X” is the kind of detail that actually decides the match.
| Recall pattern | Product examples consumers search | Real recall factor | Why the headline can mislead |
|---|---|---|---|
| Nitrosamine impurity | Valsartan, losartan, irbesartan, and ARB combinations | Affected manufacturer, process, lot, and distribution period | The same active ingredient can remain available from unaffected suppliers |
| Combination product scope | Valsartan-HCTZ, losartan-HCTZ, amlodipine-valsartan | Full formula and strength pair | Patients may remember only one ingredient and miss the combination wording |
| Manufacturer-specific action | Generic ARB tablets from named labelers | Labeler and NDC | The pharmacy name is not the drug manufacturer |
| Lot-specific recall | Specific bottles within a broader product family | Lot number and expiration date | A similar bottle from another lot may not be affected |
| Historical recall resurfacing | Older valsartan or losartan notices found in search results | Date, distribution status, and current inventory | Old notices can look current when shared without context |
The FDA blood pressure medication recall list should therefore be treated as a traceability tool. It is not a reason to assume every ARB is unsafe. It is also not a reason to ignore an ARB recall because a prior bottle was unaffected. Each refill can have a different manufacturer, lot, and expiration date.
For a narrower look at one of the most common patient questions, see our guide on how to know if your losartan has been recalled. It follows the same lot-level logic that applies across valsartan, irbesartan, and ARB combination products.
Many consumers associate blood pressure medication recalls only with nitrosamines. That is understandable, but it is incomplete. FDA drug recalls can happen for several reasons, and the recall reason changes the action you should take.
Impurity recalls receive the most attention because the defect is invisible and can raise long-term exposure concerns. Nitrosamine-related ARB recalls are the best-known example in blood pressure therapy, but impurity control is a broader manufacturing issue. A recall notice may identify the impurity, describe affected lots, and explain whether patients should contact their pharmacist before stopping therapy.
Potency failures create a different risk. A subpotent tablet may not control blood pressure as expected. A superpotent tablet may expose some patients to more drug than intended. Dissolution failures sit in the same practical category: the tablet may contain the stated amount of active ingredient but fail to release it properly. For chronic cardiovascular medications, treatment performance matters because uncontrolled blood pressure can create its own risk.
Labeling and packaging errors are also real recall drivers. A wrong strength statement, wrong package insert, bottle mix-up, or missing instruction can create medication-use errors even if the active ingredient itself passed chemical testing. These recalls are especially important for older adults, caregivers, and households managing several prescriptions.
Manufacturing quality deviations can lead to recall actions when a company or FDA identifies a process problem that affects confidence in the product. These notices can sound less urgent than contamination headlines, but they still deserve careful matching because the product may not meet specifications.
| FDA recall reason | How it can affect a blood pressure medication | What a consumer should verify | Typical next action |
|---|---|---|---|
| Nitrosamine or other impurity | Product may contain an unwanted chemical impurity above acceptable limits | Drug name, manufacturer, lot, NDC, and distribution dates | Contact the pharmacy about replacement stock and whether to continue until replaced |
| Subpotency or superpotency | Dose delivered may be lower or higher than labeled | Strength, dosage form, manufacturer, and lot | Ask pharmacist or prescriber about clinical risk and replacement timing |
| Dissolution or stability failure | Tablet may not release or remain stable as expected | Dosage form, expiration date, and affected lots | Keep the bottle and confirm whether your fill is in scope |
| Labeling error | Package may show wrong strength, missing information, or incorrect instructions | Full label, insert, bottle contents, and pharmacy record | Stop relying on memory and have the pharmacy verify the dispensed product |
| Packaging mix-up | Bottle or carton may contain the wrong product or wrong count | Imprint, package details, and prescription label | Separate the bottle and call the pharmacy immediately |
| Manufacturing quality deviation | Product may fail quality standards even if no visible defect exists | Lot and recall classification | Follow the notice and replacement instructions |
The recall class helps prioritize urgency, but it does not replace professional guidance. A Class I recall deserves immediate attention because it reflects a reasonable probability of serious health consequences. Class II and Class III recalls may still require action, especially when the product is part of a daily regimen. The key is to balance two risks: the recall risk and the risk of interrupting treatment without a replacement plan.
That balance is why patients should not throw away the bottle as the first move. The bottle contains the evidence needed for a pharmacist to confirm whether the recall applies. If the product is affected, the same bottle may also be needed for return, replacement, reimbursement, or adverse-event reporting.
For broader medication recall response steps beyond hypertension drugs, our guide on what to do if your medication is recalled covers the same decision path across prescription and over-the-counter products.
A reliable recall check starts before you search. Pull the original bottle, carton, blister pack, or pharmacy paperwork. If the tablets are already in a pill organizer, keep the organizer aside but use the source bottle if possible. A loose pill without packaging is much harder to match.
Look for these fields:
The manufacturer or labeler is especially important. Consumers often confuse the pharmacy, wholesaler, brand owner, and manufacturer. The name on the prescription label may include several parties, but recall notices usually identify the labeler or recalling firm. If the label is unclear, ask the pharmacist to read the NDC and supplier information from the pharmacy system.
Use this checklist when reviewing any FDA blood pressure medication recall list notice.
The checklist is designed to prevent the two most common errors: continuing an affected product because the recall was too hard to interpret, or stopping an unaffected medication because the headline sounded broad. Both errors are avoidable when you treat the bottle as the source of truth.
If you manage prescriptions for more than one person, build a small recall record for each refill. A phone photo of the label, lot number, and tablet appearance can save time later. This is especially useful for caregivers who refill weekly organizers. Once the tablets are separated from the package, lot-level confirmation becomes harder.
For households that track several manufacturers or generic suppliers, the brand recall lookup can help you see whether a labeler has current or historical recall activity in the same product family. Brand or manufacturer history does not prove that your bottle is affected, but it gives useful context before you call the pharmacy.
Medication recalls can feel isolated because they involve personal health decisions, but they are part of a much larger consumer safety system. RecallTracker’s database includes {{RECALL_COUNT}} recalls from {{AGENCY_LIST}}, with {{FDA_COUNT}} FDA records inside that broader total. In 2025, tracked agencies recorded {{RECALLS_2025}} recall actions, and {{RECALLS_2026_YTD}} have been recorded so far in {{CURRENT_YEAR}}.
That scale matters because consumers now see recall alerts across food, vehicles, medical devices, toys, appliances, and medications. A person may receive a food recall alert in the morning, a vehicle recall notice in the mail, and then see a social post about losartan at night. The categories are different, but the mental load is the same: determine whether the product in your home is actually affected.
Blood pressure medication recalls have several traits that make them more confusing than many consumer product recalls:
That is why recall trend context should not replace product matching. Trend data tells you where recall activity is concentrated. It does not tell you whether your specific losartan, valsartan, irbesartan, amlodipine, lisinopril, or metoprolol bottle is affected.
Still, trends are useful. If FDA recall activity rises in a drug category, patients can become more disciplined about saving packaging and checking refill labels. If a manufacturer appears repeatedly in recall records, consumers can ask sharper questions at the pharmacy. If multiple agencies show elevated recall activity in the same month, families may decide to centralize product tracking rather than relying on memory.
You can view recall trends to compare FDA activity with other agency data, including {{CPSC_COUNT}} CPSC recalls and {{NHTSA_COUNT}} NHTSA recalls. For drug-specific decisions, use those trends as context and the bottle as evidence.
If the FDA blood pressure medication recall list appears to match your bottle, slow down and separate the tasks: secure the product, confirm the match, arrange replacement, and protect treatment continuity.
Start by separating the suspect bottle from other medications so it cannot be taken by mistake. Do not throw it away unless the recall notice or pharmacist tells you to. Keep the label visible and take photos of the drug name, strength, lot number, expiration date, NDC, and tablet appearance.
Next, call the dispensing pharmacy. Ask direct questions:
If the pharmacy confirms a match, ask for the replacement plan in practical terms. Some recalls are handled through return and replacement. Others require a new prescription if a different drug or strength is needed. If there is a shortage or supplier problem, the pharmacist may need to coordinate with the prescriber.
Do not assume that “recalled” always means “stop tonight.” Some notices do advise immediate stop-use. Others tell patients not to discontinue important therapy until they have a replacement because the risk of untreated high blood pressure may outweigh the risk from short-term continued use. That is not something to decide from a headline.
Your prescriber matters when the recall affects medication availability or when the replacement is not equivalent. A different manufacturer of the same drug may be straightforward. A switch from one ARB to another, or from an ARB to an ACE inhibitor, may require clinical judgment. Patients with kidney disease, heart failure, pregnancy considerations, electrolyte issues, or multiple cardiovascular medications should be especially careful about unsupervised changes.
For historical context on how a broad drug recall memory can persist for years, our explainer on recalled blood pressure medications breaks down why ARB recalls still influence searches even when current notices are narrower.
The names most often searched include valsartan, losartan, irbesartan, valsartan-hydrochlorothiazide, losartan-hydrochlorothiazide, quinapril combinations, amlodipine-valsartan, lisinopril products, and metoprolol products. ARBs such as valsartan, losartan, and irbesartan receive the most recall attention because of the nitrosamine impurity recall history. A search result does not prove your bottle is affected. The deciding fields are manufacturer, NDC, lot number, strength, dosage form, and expiration date.
Do not stop a blood pressure medication only because the generic name appears in a search result. First confirm whether your exact bottle matches the recall notice. If it does, call the pharmacy and ask whether to continue until replacement stock is ready. Some recall notices require immediate stop-use, but many chronic-medication recalls require a replacement plan because untreated hypertension can create its own health risk.
Use the original bottle or carton. Look for the manufacturer or labeler, NDC, lot number, expiration date, strength, and whether the drug is a combination product. Compare those details with the recall notice, then call the dispensing pharmacy to confirm the fill record. The pharmacy can often see supplier and lot information even when a consumer label is incomplete or hard to read.
Older notices remain visible because major ARB recalls created long-lasting consumer concern, especially around valsartan, losartan, and irbesartan. Search engines and social posts can resurface old notices without showing whether the affected lots are still in circulation. Always check the notice date, distribution period, product status, and your current bottle details before assuming an older recall applies today.
Give the full drug name, strength, manufacturer, NDC, lot number, expiration date, pharmacy fill date, and any tablet imprint or appearance details. Say whether the medication is still in the original bottle or has been moved into an organizer. Ask whether your exact fill is affected, whether replacement stock is available, and whether you should continue taking the current supply until the replacement is ready.